Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
0.19
Industry P/E
37.44
Debt to Equity
0
ROE
-0.23 %
ROCE
--
Div. Yield
0 %
Book Value
9.1
EPS
--
CFO
$-19.78 Mln
EBITDA
$-25.13 Mln
Net Profit
$-56.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sunshine Biopharma (SBFM)
| -58.33 | -35.23 | -55.83 | -8.09 | -75.06 | -33.48 | -65.63 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Sunshine Biopharma (SBFM)
| -44.58 | -57.50 | 345.86 | 96.25 | -97.50 | -93.18 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through... Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida. Address: 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301 Read more
CFO & Secretary
Mr. Camille Sebaaly
CFO & Secretary
Mr. Camille Sebaaly
Headquarters
Fort Lauderdale, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sunshine Biopharma Inc (SBFM) stood at $ 57 Mln as on 31-Mar-25
The share price of Sunshine Biopharma Inc (SBFM) is $1.25 (NASDAQ) as of 17-Apr-2025 16:14 EDT. Sunshine Biopharma Inc (SBFM) has given a return of -75.06% in the last 3 years.
Sunshine Biopharma Inc (SBFM) has a market capitalisation of $ 4 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sunshine Biopharma Inc (SBFM) is 0.19 times as on 17-Apr-2025, a 96% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Sunshine Biopharma Inc (SBFM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sunshine Biopharma Inc (SBFM) and enter the required number of quantities and click on buy to purchase the shares of Sunshine Biopharma Inc (SBFM).
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida. Address: 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301
The CEO & director of Mr. Camille Sebaaly. is Sunshine Biopharma Inc (SBFM), and CFO & Sr. VP is Mr. Camille Sebaaly.
There is no promoter pledging in Sunshine Biopharma Inc (SBFM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Sunshine Biopharma Inc. (SBFM) | Ratios |
|---|---|
|
Return on equity(%)
|
-24.76
|
|
Operating margin(%)
|
-11.1
|
|
Net Margin(%)
|
-16.27
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Sunshine Biopharma Inc (SBFM) was $0 Mln.
$0.03
(
